Company: CDT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001641172-25-006259
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary Proxy Statement                                                     |
| ☐ | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement                                                      |
| ☐ | Definitive Additional Materials                                                 |
| ☐ | Soliciting Material Pursuant to §240.14a-12                                     |

<div align='center'>CONDUIT PHARMACEUTICALS INC.

(Name of Registrant as Specified in its
Charter)

N/A

(Name of Person(s) Filing Proxy Statement,
if Other Than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required.                                                                                     |
| ☐ | Fee paid previously with preliminary materials.                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

<div align='center'>4581 Tamiami Trail North, Suite 200

Naples, Florida 34103

(646) 491-9132

NOTICE OF VIRTUAL SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON MONDAY, MAY 5, 2025</div>

To our stockholders:

The 2025 virtual special
meeting of stockholders (the “Special Meeting”) of Conduit Pharmaceuticals Inc., a Delaware corporation, will be held on Monday,
May 5, 2025, at 10:00 a.m., Eastern Time, for the following purpose:

| 1. | To approve one or more amendments of the Company’s Second Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio ranging from any whole number between and including 1-for-2 and 1-for-100 and in the aggregate not more than 1-for-250, inclusive, as determined by the Company’s board of directors in